Skip to content
Home/Companies/Biotech/Lexeo Therapeutics

Lexeo Therapeutics

Biotech·United States·Exited 2023·Held 2yr
Entry
2021
Hold
2yr
Exit
2023

Who owns Lexeo Therapeutics?

Lexeo Therapeutics is an American Biotech company, formerly owned by Lundbeckfonden BioCapital, exited in 2023 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Lundbeckfonden BioCapital
Investor
Lundbeckfonden BioCapital
Lundbeckfonden BioCapital · 2009 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
IPO
Exit Year
2023

More from Lundbeckfonden BioCapital

Other portfolio companies in the same fund.

QuantumCell
Active
BiotechDenmark· 2025
Kvantify
Active
Deep TechDenmark· 2024
Dania Therapeutics
Active
BiotechDenmark· 2023
Epoqe Pharma
Active
BiotechDenmark· 2021
Notify Therapeutics
Active
BiotechDenmark· 2021
Sorriso Pharmaceuticals
Active
BiotechUS· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Lexeo Therapeutics?

Lexeo Therapeutics was formerly owned by Lundbeckfonden BioCapital, exited in 2023. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue